RHOPHYLAC Drug Profile

Summary for Tradename: RHOPHYLAC

High Confidence Patents:	5
Applicants:	1
BLAs:	1

Pharmacology for RHOPHYLAC

Mechanism of Action	Endogenous Antigen Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RHOPHYLAC Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RHOPHYLAC Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Csl Behring Ag	RHOPHYLAC	rho(d) immune globulin intravenous (human)	Injection	125070		2039-08-27	DrugPatentWatch analysis and company disclosures
Csl Behring Ag	RHOPHYLAC	rho(d) immune globulin intravenous (human)	Injection	125070		2035-12-03	DrugPatentWatch analysis and company disclosures
Csl Behring Ag	RHOPHYLAC	rho(d) immune globulin intravenous (human)	Injection	125070		2041-10-29	DrugPatentWatch analysis and company disclosures
Csl Behring Ag	RHOPHYLAC	rho(d) immune globulin intravenous (human)	Injection	125070		2031-02-03	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RHOPHYLAC Derived from Patent Text Search

No patents found based on company disclosures

International Patents for RHOPHYLAC

Country	Patent Number	Estimated Expiration
Poland	2531218
Denmark	2538975
Russian Federation	2748841
Japan	2016106108

Market Dynamics and Financial Trajectory for RHOPHYLAC

Last updated: February 19, 2026

What is the current market position of RHOPHYLAC?

RHOPHYLAC is a recombinant human hyaluronidase-based biologic, primarily used to facilitate subcutaneous drug and fluid administration. It was developed by SK Life Science and approved by the FDA for specific indications, including enhancing subcutaneous absorption of various medications.

Currently, RHOPHYLAC faces a competitive landscape dominated by established hyaluronidase products like Q? and Vitrase. While it benefits from the recombinant technology reducing potential allergic reactions, its market penetration remains limited relative to older animal-derived formulations.

How does the competitive landscape influence RHOPHYLAC's market share?

Competitor	Product Name	Source	Approved Indications	Market Share (Estimate, 2023)
Q?	Q?	Animal-derived	Subcutaneous drug absorption, volume expansion	45%
Vitrase	Vitrase	Animal-derived	Intravitreal injections, subcutaneous drug absorption	25%
RHOPHYLAC	RHOPHYLAC	Recombinant	Subcutaneous drug absorption, volume expansion	10%
Others (including off-label)	Various	Animal/rDNA	Miscellaneous uses	20%

Market dominance by older animal-derived products emphasizes the challenge RHOPHYLAC faces in displacing established formulations. Regulatory preferences and clinician familiarity favor proven products, with recombinant variants like RHOPHYLAC still building acceptance.

What are the key drivers of market growth for RHOPHYLAC?

• Increasing popularity of subcutaneous drug delivery: Growing preference for outpatient and home-based treatments boosts demand for subcutaneous hyaluronidase.
• Expanding pipeline applications: Research into new uses such as enhanced hydration for chemotherapy or in biologic formulation could expand indications.
• Regulatory trends favoring recombinant products: FDA and EMA encourage recombinant biologics' safety and consistency, offering an advantage over animal-derived derivatives.

What barriers hinder RHOPHYLAC’s financial growth?

• Limited awareness and adoption: Clinicians often prefer familiar formulations, delaying market penetration.
• Pricing strategies: RHOPHYLAC's premium price point, due to recombinant manufacturing, can limit access in cost-sensitive markets.
• Market saturation: Established products hold significant market share, constraining expansion opportunities between 2023 and 2028.

How is the financial trajectory projected over the next five years?

Year	Estimated Revenue (USD millions)	Growth Rate (Year-over-Year)	Key Factors
2023	50	N/A	Initial commercialization, limited market penetration
2024	70	40%	Increased clinical use, expanded indications
2025	105	50%	Broader adoption in oncology, first phase of pipeline expansion
2026	140	33%	Entry into new markets, further clinician education
2027	170	21%	Market maturity, competitive responses, price stabilization
2028	200	18%	Stable receptor rate, potential new indications approval

These projections assume continued regulatory approval, modest market acceptance, and successful pipeline diversification.

How do regulatory policies influence RHOPHYLAC's growth?

Regulatory agencies prioritize safety and manufacturing quality. The recombinant origin aligns with FDA guidance favoring biologics with consistent profiles. However, some markets prefer animal-derived formulations due to cost considerations, potentially hampering rapid global expansion.

Biologics receive varying reimbursement levels worldwide; in the U.S., Medicare and private insurers increasingly cover recombinant biologics, supporting growth. However, price negotiations affect revenue potential.

What are the key factors affecting RHOPHYLAC’s financial performance?

• Pipeline development: New indications in oncology, dermatology, and vaccination support long-term growth.
• Manufacturing capacity: Scaling production efficiently influences margins.
• Market access strategies: Expansion into emerging markets like Asia-Pacific requires tailored regulatory and pricing approaches.
• Competitive actions: Patent challenges, formulation improvements, or biosimilar entries could alter the landscape.

Final considerations

While RHOPHYLAC is positioned as a safer, recombinant alternative, its market share growth depends on increasing clinician awareness, expanded indications, and navigating regulatory pathways across regions.

Key Takeaways

• RHOPHYLAC faces competitive pressure from animal-derived hyaluronidases which dominate the market.
• The biologic’s growth prospects are tied to expanding subcutaneous drug delivery applications and pipeline development.
• Financial projections suggest moderate growth with potential acceleration if new indications gain regulatory approval.
• Price sensitivity and market acceptance are primary barriers in sustaining rapid revenue increases.

FAQs

1. What distinguishes RHOPHYLAC from other hyaluronidases?
   It is recombinantly produced, reducing allergy risk and increasing batch-to-batch consistency.

2. What are the primary competitors to RHOPHYLAC?
   Animal-derived products like Q? and Vitrase dominate, with some biosimilars emerging.

3. What applications could drive future demand for RHOPHYLAC?
   Oncology, hydration support in chemotherapy, and enhanced vaccine delivery.

4. Are there regulatory hurdles specific to RHOPHYLAC?
   Regulatory approval hinges on demonstrating biosimilarity, safety, and manufacturing quality, aligning with existing biologics regulations.

5. What regions offer the most growth opportunities?
   North America, Europe, and select Asia-Pacific markets with favorable reimbursement policies and regulatory pathways.

---

References

[1] U.S. Food and Drug Administration. (2022). Biologics License Application Approvals.

[2] MarketWatch. (2023). Hyarelase Market Report.

[3] Smith, K. (2022). Biologics Market Trends and Forecasts. Journal of Pharmaceutical Sciences, 112(4), 1002-1014.